The United States Court of Appeals for the Federal Circuit (CAFC) on Tuesday affirmed an invalidity decision of the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB) in Immunex Corporation v. Sanofi-Aventis U.S. LLC. Considering the intrinsic and extrinsic evidence, the CAFC agreed with the PTAB’s construction of the disputed claim term, “human antibodies,” and affirmed the holding that the patent in suit was invalid as obvious.

Full Article Available Here